admin

The journey to leadership positions in finance is often paved with traditional pathways—finance degrees from renowned schools, internships at investment banks, and an early start in analyst roles. Yet Kathryn Glass, co-head of Federated Hermes’ high-yield fixed-income group, defies the mold. Her foray into the financial realm only began after an educational detour through Japanese
In an era where technological supremacy is intertwined with national security, the news of GlobalFoundries considering a merger with Taiwan-based United Microelectronics could be seen as a game changer. This potential union is not merely a business maneuver; it symbolizes a substantial strategic shift in global semiconductor manufacturing. As competition from China looms, and tensions
The international film market is becoming increasingly dynamic, as seen this past weekend with Jason Statham’s “A Working Man” making significant waves. Garnering a global $30.2 million debut—including an impressive $15 million from overseas—this latest offering highlights a resurgence in the action genre. While some may dismiss such films as mere entertainment, “A Working Man”
As we barrel through 2025, economic uncertainties loom large, largely stemming from the aggressive tariff policies of the previous administration. This turbulence has triggered a paradoxical situation where falling stock prices, tied to fundamental market challenges, could indeed present ripe opportunities for disciplined investors. Markets have been whipsawed, igniting both fear and cautious optimism. Yes,
Novo Nordisk has recently taken a bold step forward in diabetes treatment with its once-daily oral medication, Rybelsus. The company’s announcement at the American College of Cardiology’s Annual Scientific Session revealed that Rybelsus shows significant cardiovascular benefits in patients with Type 2 diabetes, particularly those with existing heart disease. With a 14% reduction in the
The recent expiration of Vanguard’s pivotal patent has created a noticeable ripple in the exchange-traded fund (ETF) arena, a sector that’s no stranger to upheaval. What was once Vanguard’s unique advantage—a structure that minimized tax liabilities for investors—now opens the door for competitors to innovate and challenge the status quo. The implications of this change
Illumina’s narrative is one of incredible promise tarnished by a series of highly publicized missteps. Once the undisputed titan of the gene-sequencing arena, the company now sits precariously on the brink of irrelevance, its valuation slumping from a staggering $70 billion to a disheartening $12.67 billion. This steep decline raises serious questions about its leadership
In a stunning turn of events, a class-action lawsuit against Elon Musk and his family office, Excession, has been given the green light to proceed in federal court. This pivotal case, Rasella v. Musk, highlights the murkiness surrounding the billionaire’s stock dealings and raises serious questions about the ethical implications of his transparency—or lack thereof.